{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T02:14:26Z","timestamp":1778897666123,"version":"3.51.4"},"reference-count":23,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,27]],"date-time":"2023-06-27T00:00:00Z","timestamp":1687824000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002322","name":"CAPES","doi-asserted-by":"publisher","award":["88882.434900\/2019-01"],"award-info":[{"award-number":["88882.434900\/2019-01"]}],"id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013101","name":"National Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013101","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","award":["305110\/2018-7"],"award-info":[{"award-number":["305110\/2018-7"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology, Transfusion and Cell Therapy"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.htct.2023.06.001","type":"journal-article","created":{"date-parts":[[2023,7,5]],"date-time":"2023-07-05T18:18:45Z","timestamp":1688581125000},"page":"268-272","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Peripheral lymphocyte subsets as predicting factors for molecular recurrence after imatinib discontinuation in a phase 2 imatinib discontinuation trial in patients with chronic myeloid leukemia"],"prefix":"10.1016","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9223-9139","authenticated-orcid":false,"given":"Arthur Gomes Oliveira","family":"Braga","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7975-0805","authenticated-orcid":false,"given":"Katia Borgia","family":"Barbosa Pagnano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5776-6435","authenticated-orcid":false,"given":"Marina Dal'B\u00f3 Pelegrini","family":"Campioni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4720-6669","authenticated-orcid":false,"given":"Ana Beatriz Pascoal","family":"Lopes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gislaine Oliveira","family":"Duarte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0742-8846","authenticated-orcid":false,"given":"Konradin","family":"Metze","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6516-1265","authenticated-orcid":false,"given":"Irene","family":"Lorand-Metze","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.htct.2023.06.001_bib0001","doi-asserted-by":"crossref","unstructured":"Ross D.M., Branford S., Seymour J.F., Schwarer A.P., Arthur C., Yeung D.T. et al. Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease : results from the TWISTER study, 122 (2013) 1\u20134. https:\/\/doi.org\/10.1182\/blood-2013-02-483750.","DOI":"10.1182\/blood-2013-02-483750"},{"key":"10.1016\/j.htct.2023.06.001_bib0002","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1182\/blood-2021-148369","article-title":"FINAL analysis of a PAN European STOP tyrosine kinase inhibitor trial in chronic myeloid leukemia : the EURO-SKI study","volume":"138","author":"Mahon","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.htct.2023.06.001_bib0003","doi-asserted-by":"crossref","first-page":"461","DOI":"10.7326\/M17-1094","article-title":"Treatment-free remission after second-line nilotinib treatment in patients with chronic myeloid leukemia in chronic phase","volume":"168","author":"Mahon","year":"2018","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.htct.2023.06.001_bib0004","first-page":"95","article-title":"Efficacy and safety of pioglitazone in a phase 1\/2 imatinib discontinuation trial (<scp>EDI-PIO<\/scp>) in chronic myeloid leukemia with deep molecular response","author":"Pagnano","year":"2020","journal-title":"Am J Hematol"},{"key":"10.1016\/j.htct.2023.06.001_bib0005","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1080\/10428194.2019.1675879","article-title":"Dasatinib discontinuation in patients with chronic-phase chronic myeloid leukemia and stable deep molecular response: the DASFREE study","volume":"61","author":"Shah","year":"2020","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.htct.2023.06.001_bib0006","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2021.106516","article-title":"MR 4log and low levels of NK cells are associated with higher molecular relapse after imatinib discontinuation: results of a prospective trial","volume":"101","author":"Seguro","year":"2021","journal-title":"Leuk Res"},{"key":"10.1016\/j.htct.2023.06.001_bib0007","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1038\/s41375-021-01238-w","article-title":"Improving outcomes in chronic myeloid leukemia through harnessing the immunological landscape","volume":"35","author":"Hsieh","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.htct.2023.06.001_bib0008","first-page":"298","article-title":"Predictive factors for successful imatinib cessation in chronic myeloid leukemia patients treated with imatinib","volume":"122","author":"Ilander","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.htct.2023.06.001_bib0009","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2017.165001","article-title":"Natural killer-cell counts are associated with molecular relapse-free survival after imatinib discontinuation in chronic myeloid leukemia: the IMMUNOSTIM study","volume":"102","author":"Rea","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.htct.2023.06.001_bib0010","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1038\/nature15248","article-title":"Erosion of the chronic myeloid leukaemia stem cell pool by PPAR\u03b3 agonists","volume":"525","author":"Prost","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.htct.2023.06.001_bib0011","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1038\/leu.2015.29","article-title":"Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia","volume":"29","author":"Cross","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.htct.2023.06.001_bib0012","first-page":"10","article-title":"EuroFlow-based flowcytometric diagnostic screening and classification of primary immunodeficiencies of the lymphoid system","author":"van Dongen","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.htct.2023.06.001_bib0013","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1002\/cncr.30490","article-title":"Pioglitazone together with imatinib in chronic myeloid leukemia: a proof of concept study","volume":"123","author":"Rousselot","year":"2017","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.htct.2023.06.001_bib0014","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s12288-022-01561-x","article-title":"Supplemental pioglitazone to patients of CML with suboptimal TKI response: a pragmatic pilot study","volume":"39","author":"Yanamandra","year":"2023","journal-title":"Indian J Hematol Blood Transfus"},{"key":"10.1016\/j.htct.2023.06.001_bib0015","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1002\/jha2.550","article-title":"De-escalation or discontinuation of tyrosine kinase inhibitor in patients with chronic myeloid leukemia: a multicentral, open-label, prospective trial in China","volume":"3","author":"Luo","year":"2022","journal-title":"EJHaem"},{"key":"10.1016\/j.htct.2023.06.001_bib0016","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1111\/bjh.16718","article-title":"Successful treatment-free remission in chronic myeloid leukaemia and its association with reduced immune suppressors and increased natural killer cells","volume":"191","author":"Irani","year":"2020","journal-title":"Br J Haematol"},{"key":"10.1016\/j.htct.2023.06.001_bib0017","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1007\/s00277-021-04606-9","article-title":"Profiles of NK cell subsets are associated with successful tyrosine kinase inhibitor discontinuation in chronic myeloid leukemia and changes following interferon treatment","volume":"100","author":"Kong","year":"2021","journal-title":"Ann Hematol"},{"key":"10.1016\/j.htct.2023.06.001_bib0018","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.autrev.2003.09.001","article-title":"CD4+ CD8+ double positive (DP) T cells in health and disease","volume":"3","author":"Parel","year":"2004","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.htct.2023.06.001_bib0019","doi-asserted-by":"crossref","DOI":"10.1016\/j.exger.2021.111450","article-title":"Immunophenotypic characterization of double positive T lymphocytes in Cuban older adults","volume":"152","author":"Marrero","year":"2021","journal-title":"Exp Gerontol"},{"key":"10.1016\/j.htct.2023.06.001_bib0020","doi-asserted-by":"crossref","first-page":"e8437","DOI":"10.1371\/journal.pone.0008437","article-title":"Double positive CD4CD8 \u03b1\u03b2 T cells: a new tumor-reactive population in human melanomas","volume":"5","author":"Desfran\u00e7ois","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.htct.2023.06.001_bib0021","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1007\/s12032-021-01551-5","article-title":"Metabolic shift of chronic myeloid leukemia patients under imatinib\u2013pioglitazone regimen and discontinuation","volume":"38","author":"P\u00f3voa","year":"2021","journal-title":"Med Oncol"},{"key":"10.1016\/j.htct.2023.06.001_bib0022","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1038\/s41467-020-14332-x","article-title":"Impaired lipid biosynthesis hinders anti-tumor efficacy of intratumoral iNKT cells","volume":"11","author":"Fu","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.htct.2023.06.001_bib0023","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s13098-015-0068-6","article-title":"Pioglitazone alters monocyte populations and stimulates recent thymic emigrants in the BBDZR\/Wor type 2 diabetes rat model","volume":"7","author":"Gao","year":"2015","journal-title":"Diabetol Metab Syndr"}],"container-title":["Hematology, Transfusion and Cell Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2531137923001104?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2531137923001104?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T01:58:03Z","timestamp":1778896683000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2531137923001104"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":23,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["S2531137923001104"],"URL":"https:\/\/doi.org\/10.1016\/j.htct.2023.06.001","relation":{},"ISSN":["2531-1379"],"issn-type":[{"value":"2531-1379","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Peripheral lymphocyte subsets as predicting factors for molecular recurrence after imatinib discontinuation in a phase 2 imatinib discontinuation trial in patients with chronic myeloid leukemia","name":"articletitle","label":"Article Title"},{"value":"Hematology, Transfusion and Cell Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.htct.2023.06.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Associa\u00e7\u00e3o Brasileira de Hematologia, Hemoterapia e Terapia Celular. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}